Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease
Autore:
Shoulson, I; Penney, J; McDermott, M; Kieburtz, K; Schwid, SR; Kayson, E; Chase, T; Fahn, S; Greenamyre, JT; Lang, A; Siderowf, A; Pearson, N; Harrison, M; Rost-Ruffner, E; Colcher, A; Lloyd, M; Matthews, M; Pahwa, R; McGuire, D; Lew, MF; Schuman, S; Marek, K; Broshjeit, S; Factor, S; Brown, D; Feigin, A; Mazurkiewicz, J; Ford, B; Jennings, D; Dillon, S; Comella, C; Blasucci, L; Janko, K; Shulman, L; Wiener, W; Bateman-Rodriguez, D; Carrion, A; Suchowersky, O; Lafontaine, AL; Pantella, C; Siemers, E; Belden, J; Davies, R; Lannon, M; Grimes, D; Gray, P; Martin, W; Kennedy, L; Adler, C; Newman, S; Hammerstad, J; Stone, C; Lewitt, P; Bardram, K; Mistura, K; Miyasaki, J; Johnston, L; Cha, JHJ; Tennis, M; Panisset, M; Hall, J; Tetrud, J; Friedlander, J; Hauser, R; Gauger, L; Rodnitzky, R; Deleo, A; Dobson, J; Seeberger, L; Dingmann, C; Tarsy, D; Ryan, P; Elmer, L; Ruzicka, D; Stacy, M; Brewer, M; Locke, B; Baker, D; Casaceli, C; Day, D; Florack, M; Hodgeman, K; Laroia, N; Nobel, R; Orme, C; Rexo, L; Rothenburgh, K; Sulimowicz, K; Watts, A; Wratni, E; Tariot, P; Cox, C; Leventhal, C; Alderfer, V; Craun, AM; Frey, J; McCree, L; McDermott, J; Cooper, J; Holdich, T; Read, B;
Indirizzi:
Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA Univ Rochester Rochester NY USA 14642 ept Neurol, Rochester, NY 14642 USA Clin Trials Coordinat Ctr, Rochester, NY USA Clin Trials Coordinat Ctr Rochester NY USA rdinat Ctr, Rochester, NY USA Univ Virginia, Ctr Hlth Sci, Charlottesville, VA USA Univ Virginia Charlottesville VA USA r Hlth Sci, Charlottesville, VA USA Penn Hosp, Philadelphia, PA 19107 USA Penn Hosp Philadelphia PA USA 19107Penn Hosp, Philadelphia, PA 19107 USA Univ Kansas, Med Ctr, Kansas City, KS 66103 USA Univ Kansas Kansas City KS USA 66103 , Med Ctr, Kansas City, KS 66103 USA Univ So Calif, Sch Med, Los Angeles, CA USA Univ So Calif Los Angeles CA USA So Calif, Sch Med, Los Angeles, CA USA Yale Univ, Sch Med, New Haven, CT USA Yale Univ New Haven CT USAYale Univ, Sch Med, New Haven, CT USA Albany Med Coll, Albany, NY 12208 USA Albany Med Coll Albany NY USA 12208Albany Med Coll, Albany, NY 12208 USA N Shore Univ Hosp, Manhasset, NY USA N Shore Univ Hosp Manhasset NY USAN Shore Univ Hosp, Manhasset, NY USA Columbia Presbyterian Med Ctr, New York, NY 10032 USA Columbia Presbyterian Med Ctr New York NY USA 10032 ew York, NY 10032 USA Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA Rush Presbyterian St Lukes Med Ctr Chicago IL USA 60612 ago, IL 60612 USA Univ Miami, Miami, FL 33152 USA Univ Miami Miami FL USA 33152Univ Miami, Miami, FL 33152 USA Univ Calgary, Med Clin, Calgary, AB, Canada Univ Calgary Calgary AB Canada iv Calgary, Med Clin, Calgary, AB, Canada Indiana Univ, Sch Med, Indianapolis, IN USA Indiana Univ Indianapolis IN USA ana Univ, Sch Med, Indianapolis, IN USA Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA Brown Univ Pawtucket RI USA 02860 Hosp Rhode Isl, Pawtucket, RI 02860 USA Ottawa Civic Hosp, Ottawa, ON K1Y 4E9, Canada Ottawa Civic Hosp Ottawa ONCanada K1Y 4E9 sp, Ottawa, ON K1Y 4E9, Canada Univ Alberta, Edmonton, AB, Canada Univ Alberta Edmonton AB CanadaUniv Alberta, Edmonton, AB, Canada Mayo Clin, Scottsdale, AZ USA Mayo Clin Scottsdale AZ USAMayo Clin, Scottsdale, AZ USA Oregon Hlth Sci Univ, Portland, OR 97201 USA Oregon Hlth Sci Univ Portland OR USA 97201 i Univ, Portland, OR 97201 USA Sinai Clin Neurosci Ctr, W Bloomfield, MI USA Sinai Clin Neurosci Ctr W Bloomfield MI USA ci Ctr, W Bloomfield, MI USA Toronto Western Hosp, Toronto, ON M5T 2S8, Canada Toronto Western Hosp Toronto ON Canada M5T 2S8 oronto, ON M5T 2S8, Canada Massachusetts Gen Hosp, Boston, MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 Gen Hosp, Boston, MA 02114 USA McGill Ctr Studies Aging, Montreal, PQ, Canada McGill Ctr Studies Aging Montreal PQ Canada Aging, Montreal, PQ, Canada Parkinsons Inst, Sunnyvale, CA USA Parkinsons Inst Sunnyvale CA USAParkinsons Inst, Sunnyvale, CA USA Univ S Florida, Tampa, FL USA Univ S Florida Tampa FL USAUniv S Florida, Tampa, FL USA Univ Iowa, Iowa City, IA USA Univ Iowa Iowa City IA USAUniv Iowa, Iowa City, IA USA Colorado Neurol Inst, Englewood, CO USA Colorado Neurol Inst Englewood COUSA ado Neurol Inst, Englewood, CO USA Beth Israel Deaconess Med Ctr, Boston, MA USA Beth Israel Deaconess Med Ctr Boston MA USA ness Med Ctr, Boston, MA USA Univ Michigan, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 iv Michigan, Ann Arbor, MI 48109 USA Barrow Neurol Inst, Phoenix, AZ 85013 USA Barrow Neurol Inst Phoenix AZ USA 85013 eurol Inst, Phoenix, AZ 85013 USA
Titolo Testata:
NEUROLOGY
fascicolo: 4, volume: 56, anno: 2001,
pagine: 455 - 462
SICI:
0028-3878(20010227)56:4<455:ARCTOR>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEVODOPA-INDUCED DYSKINESIAS; MONOAMINE-DEPLETED RATS; NMDA RECEPTOR SUBUNITS; L-DOPA; GLUTAMATE ANTAGONIST; RESPONSE ALTERATIONS; SUBTHALAMIC NUCLEUS; BASAL GANGLIA; MONKEYS; PHOSPHORYLATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Schwid, SR Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave,Box 605, Rochester, NY 14642 USA Univ Rochester 601 Elmwood Ave,Box 605 Rochester NYUSA 14642 A
Citazione:
I. Shoulson et al., "A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease", NEUROLOGY, 56(4), 2001, pp. 455-462

Abstract

Background: Preclinical studies suggest that glutamate antagonists help ameliorate motor fluctuations in patients with PD treated with levodopa. Methods: In a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study, the authors assessed the safety, tolerability, and efficacy of the glutamate receptor blocker remacemide hydrochloride in 279 patients with motor fluctuations treated with levodopa. The primary objective was to assess the short-term tolerability and safety of four dosage levels of remacemide during 7 weeks of treatment. Patients were also monitored with home diaries and the Unified PD Rating Scale (UPDRS) to collect preliminary data on treatment efficacy. Results: Remacemide was well tolerated up to a dosage of 300 mg/d on a twice daily schedule and 600 mg/d on a four times daily schedule. The most common dosage-related adverse events were dizziness and nausea, as observed in previous studies of remacemide. Thepercent "on" time and motor UPDRS scores showed trends toward improvement in the patients treated with 150 and 300 mg/d remacemide compared with placebo-treated patients, although these improvements were not significant. Conclusion: Remacemide is a safe and tolerable adjunct to dopaminergic therapyfor patients with PD and motor fluctuations. Although this study had limited power to detect therapeutic effects, the observed improvement is consistent with studies of non-human primates with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian signs and symptoms. Additional studies are warranted to confirm these results over an extended period of observation, and to explore the potential neuroprotective effects of remacemide in slowing the progression of PD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 10:40:05